Physical activity in chronic respiratory conditions: Assessing risks for physical activity clearance and prescription

Canadian Family Physician

Volumn 58, Issue 7, 2012, Pages 761-764

  Burr, Jamie F ^a   Davidson, Warren ^b   Shephard, Roy J ^c   Eves, Neil ^d  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Ottawa Hospital General Campus   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; CORTICOSTEROID;

AEROBIC EXERCISE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; COMORBIDITY; ENVIRONMENTAL FACTOR; EXERCISE TOLERANCE; HUMAN; MORTALITY; PHYSICAL ACTIVITY; PRESCRIPTION; QUALITY OF LIFE; RISK FACTOR; SHORT SURVEY; SMOKING;

ASTHMA; EXERCISE THERAPY; EXERCISE TOLERANCE; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK ASSESSMENT;

EID: 84864653772     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (13)

1. Chronic respiratory diseases facts and figures. Ottawa, ON: Public Health Agency of Canada; 2007. Available from: www.phac-aspc.gc.ca/cd-mc/ crd-mrc/crd-figures-mrc-figures-eng.php#t1-1. Accessed 2012 May 11.
2. Paz-Díaz H, Montes de Oca M, López JM, Celli BR. Pulmonary rehabilitation improves depression, anxiety, dyspnea and health status in patients with COPD. Am J Phys Med Rehabil 2007;86(1):30-6. (Pubitemid 46360561)
3. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997;349(9064):1498- 504. (Pubitemid 27216360)
4. Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970-2002. JAMA 2005;294(10):1255-9. (Pubitemid 41352114)
5. Eves ND, Davidson WJ. Evidence-based risk assessment and recommendations for physical activity clearance: respiratory disease. Appl Physiol Nutr Metab 2011;36(Suppl 1):S80-100.
6. Warburton DER, Jamnik VK, Bredin SSD, Gledhill N. The Physical Activity Readiness Questionnaire (PARQ+) and electronic Physical Activity Readiness Medical Examination (ePARmed-X+). Health Fitness J Can 2011;4(2):3-23.
7. Crisafulli E, Costi S, Luppi F, Cirelli G, Cilione C, Coletti O, et al. Role of comorbidities in a cohort of patients with COPD undergoing pulmonary rehabilitation. Thorax 2008;63(6):487-92. Epub 2008 Jan 18.
8. Briggs DD Jr. Chronic obstructive pulmonary disease overview: prevalence, pathogenesis, and treatment. J Manag Care Pharm 2004;10(4 Suppl):S3-10.
9. De Miguel Díez J, García TG, Maestu LP. Comorbidities in COPD [article in Spanish]. Arch Bronconeumol 2010;46(Suppl 11):20-5.
10. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: role of comorbidities. Eur Respir J 2006;28(6):1245-57. (Pubitemid 44883863)
11. Chatila WM, Thomashow BM, Minai OA, Criner GJ, Make BJ. Comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008;5(4):549-55. (Pubitemid 351669185)
12. Butler J, Schrijen F, Henriquez A, Polu JM, Albert RK. Cause of the raised wedge pressure on exercise in chronic obstructive pulmonary disease. Am Rev Respir Dis 1988;138(2):350-4.
13. American Thoracic Society, American College of Chest Physicians. ATS/ACCP statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 2003;167(2):211-77. Erratum in: Am J Respir Crit Care Med 2003;167(10):1451-2.